TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05566457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs
Description: Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
Study: NCT02955966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: imaging 18F-FDG-PET/CT
Description: 18F-FDG PET Scan at Day 0, W6 and W12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
Study: NCT01475110

Intervention type: DRUG
Intervention: Imatinib
Description: Observation of Imatinib resistant patients treated with Nilotinib.
Study: NCT00874588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
Study: NCT00532766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jusline
Study: NCT02724735

Intervention type: DRUG
Intervention: NSI-189
Description: 0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
Study: NCT02668861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 4000IU/day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal Spray
Description: Budesonide Nasal Spray 128ug/d for 8 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide Nasal Spray
Description: Budesonide Nasal Spray 128ug/d for 8 week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 8 weeks
Study: NCT04602767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
Study: NCT02488291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 sufentanil
Description: with different dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5µg/ml sufentanil
Description: 0.5µg/ml sufentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Description: 0.1% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Description: 0.1% ropivacaine
Study: NCT02168972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Global mapping and ablation device
Description: During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
Study: NCT00989391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: 5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT02915783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 4 mg and 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 5 mg tablets
Study: NCT02541305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propioceptive program
Description: The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No propioceptive program
Description: The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
Study: NCT03009344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat tablets.
Study: NCT03507244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
Study: NCT04106739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
Description: This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
Description: This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary.
Study: NCT01971255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ca/04/2009/H1N1r Challenge Virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ca/04/2009/H1N1r Challenge Virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
Study: NCT01802619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inhaled Nitrogen
Description: Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
Study: NCT05330000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg/kg Voriconazole
Description: Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg/kg Voriconazole
Description: Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
Study: NCT00989391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT05330000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 mg/kg Voriconazole
Description: High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg/kg Voriconazole
Description: High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
Study: NCT04405310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma of patients with COVID-19
Description: Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma of patients with COVID-19
Description: Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (hartmann plus albumine)
Description: use of albumin 20% in 250cc of Hartmann solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (hartmann plus albumine)
Description: use of albumin 20% in 250cc of Hartmann solution
Study: NCT02684435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Dosing per approved package label
Study: NCT01862159

Intervention type: PROCEDURE
Intervention: laparoscopic gastric bypass surgery
Description: laparoscopic gastric bypass surgery
Study: NCT03210415

Intervention type: OTHER
Intervention: Observational Study Model
Description: There is no intervention for the study.

Intervention type: OTHER
Intervention: Observational Study Model
Description: There is no intervention for the study.
Study: NCT04107935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREAT-ON
Description: TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE.
Study: NCT02169726

Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
Study: NCT03795051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated Transcranial Magnetic Stimulation
Description: This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
Study: NCT03062605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine (Betadine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine (Betadine)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NaOCL
Study: NCT01009333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim Therapy at rate 5.2 Hz
Description: All subjects enrolled in this study were programmed to this rate setting for a 1-week period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim Therapy at rate 14 Hz
Description: All subjects enrolled in this study were programmed to this rate setting for a 1-week period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim Therapy
Description: All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
Study: NCT04046666

Intervention type: DEVICE
Group type: OTHER
Intervention: Functional near infrared spectroscopy
Description: Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.

Intervention type: DEVICE
Group type: OTHER
Intervention: Functional near infrared spectroscopy
Description: Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.

Intervention type: DEVICE
Group type: OTHER
Intervention: Functional near infrared spectroscopy
Description: Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Moxibustion
Description: Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm.
Study: NCT01948791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENA713
Description: The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
Study: NCT01062516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole 20 mg daily
Description: oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine 40 mg daily
Description: oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
Study: NCT00989391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: 12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT03108027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)
Study: NCT01688479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essex® cream (Schering-Plough), aqueous cream without parabens
Study: NCT02335918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of varlilumab and nivolumab
Description: Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects.
Study: NCT00696774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.
Study: NCT02139176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contract referral
Description: A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient referral
Description: A patient agrees to recruit their partner using the invitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient referral
Description: A patient agrees to recruit their partner using the invitation.
Study: NCT02401945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120
Study: NCT03108027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)